½ðÄê»á

À´Ô´£ºÖ²þâ±µÄÈË £¬×÷Õߣº  £¬£º

¶ªÄÇÐÇ £¬µ±Ìì½²µ½ÐÝÏÐÍÆÄÃภ£¬ÕæÊÇÂÑÊæ·þµÄÏíÊÜ£¡ÄãÏþµÃû £¬¹ÅÌï¶þ·Õâ¿éµØ £¬³ÔºÈÍæÀÖÒ»ÌõÁú £¬¼òÖ±ÊÇÐÑÁúµÄÑ¡Ôñ¡£ÓиãµÄÅóÓѳ£»áÎÊ £¬ÕâÀïµÄÍÆÄõêÊDz»ÊÇÂÑ»ðÌÌ£¿¾ßÌ嵨µãÔÚÄÄ¿­ÄØ£¿½ñÌì¾ÍÀ´½²½²¹ÅÌï¶þ·ÐÝÏÐÎÝÍÆÄÃµêµØµãµÄÄÇЩʶù¡£

¹ÅÌï¶þ·ÐÝÏÐÎÝÍÆÄõêµÄλÖÃ

½²µ½Õâ¼ÒÍÆÄõêภ£¬¾ßÌåλÖþÍÔÚ¹ÅÌï¶þ·µÄÖжÎ £¬ÅԱ߰¤×ż¸¸öÐÑéÏ魵IJ͹ݺͲè� £¬Î»ÖÃÕæÊÇÂѱ㵱¡£ÄãÒªÊÇ´ÓÄÏÃæ¿Ë £¬ÂéÖ±×߸öÎå°ÙÃ× £¬¿´µ½×ó±ßÓиöÐÑÁúµÄÕÐÅÆ £¬ÄÇ¿­¾ÍÊÇÁË¡£°¥ £¬½²Õæ £¬ÔçÉÏÈ¥ÍÆÄò»½ÐÈ˶à £¬ÍíÉÏ¿ËßÖ £¬¿ÉÄÜ»áÂѼ·ÈËŶ¡£

Ïà¹ØÍ¼Æ¬
ÐÑÁúµã£ºÍíÉÏ¿Ë×îºÃÌáǰԤԼ £¬Ã»È»ÂѵȵÃÈ˶¼ñ²µÃÂѵø £¬À˲ÙÐÄÇé¡£

ÍÆÄÃЧÀÍÓиãû£¿

Äã½²ÕâЧÀͺÃÇ·ºÃ£¿‡S £¬ÕæÊÇËãÂÑÃ͵ģ¡ËûÃǼÒÓйŰåµÄÍÆÄà £¬Ò²ÓÐһЩÂÑÊæ·þµÄ×ãÁÆ £¬ÍÆÄÃʦßÖ £¬ÊÖ·¨ËãµÃÉÏÐÑéÏé­¡£²»¹ýßÖ £¬ÄãÒªÊÇÏë¸ãŨˮµÄÄÇÖÖЧÀÍ £¬±ð·Ñ½²ÁË £¬ÕâÀïÕý¹æµÃºÜ £¬¸ãÂÑû¼ûµÄʲ»»áÓС£Ð§ÀÍ·½ÃæÂï £¬Ì¬¶Èµ¹ÊÇÂѺà £¬ÕкôµÃÖܵ½¡£

Ïà¹ØÍ¼Æ¬

¼Û¸ñÕ¦Ñù £¬¹ó²»¹ó£¿

˵µ½¼Û¸ñ࣠£¬ÕæÊÇÂé·³ÂѶ¼µßµÄʵ»Ý£¡ÆÕÍ¨ÍÆÄûòÐí¼¸Ê®¿é £¬×ãÁÆÉÔ΢¹óµãÒ²¾Í°ÙÀ´¿é¡£Õâ¼Û¸ñÔÚ¹ÅÌï¶þ·Õâ±ß £¬ËãÊÇÂÑÇ×ÃñÁË £¬¾¿¾¹ÆäËûµØ·½ÓÐЩ°º×еê £¬Ëæ±ã¸ã¸ã¾ÍÒª¼¸°Ù¿é £¬ÕæÊǰÇÀô¬µÄ¼Û¸ñม£×ÜÖ® £¬ÕâÀïÐÔ¼Û±ÈËãÂѸß £¬Ã»ÐÅÄã¿ËÊÔÏÂ×Ó¡£

ÔõôÕÒµ½Õâ¼Òµê£¿

Ïà¹ØÍ¼Æ¬

ÄãÒªÕÒÕâ¼Òµê £¬×î¼òµ¥µÄ²½·¥¾ÍÊÇ´ò¸ö³µ £¬¸úʦ¸µ½²¹ÅÌï¶þ·ÐÝÏÐÎÝÍÆÄõê £¬ËûÒ»Ìý¾ÍÏþµÃÔÚÄĹÕ¡£ÒªÊÇ×Ô¼º¿ª³µµÄ»° £¬¶¨Î»µ¼º½¸ã¶¨ £¬Ö±½ÓËÑ¡°¹ÅÌï¶þ·ÐÝÏÐÎÝÍÆÄõꡱ £¬µ¼º½»á´øÄãµ½ÃÅ¿Ú £¬Âѱ㵱µÃºÜ¡£


ÄǾ¿¾¹¹ÅÌï¶þ·ÐÝÏÐÎÝÍÆÄÃµêµØµãÄÑÕÒÂ𣿴ðÄã¶¼À§£¡Ö±½Óµ¼º½»òÕßÎÊ· £¬ÂѼòµ¥µÃºÜ £¬Â·ÉÏÐÑÁúµÄÈ˶¼»á¸æËßÄã¡£

¹ÅÌï¶þ·, ÐÝÏÐÎÝ, ÍÆÄõê, µØµãÅÌÎÊ, ¹ðÁøÉú»î

¡¶À¥Ã÷spaÍÆÄú¬¿ÚÄÄÀïÓС·

á°Í¼È«ÐÂÍÆ³öµÄ¡°Í¥Ôº¼¶´óÎå×ùSUV¡±á°Í¼Ì©É½X8 £¬ÖÂÁ¦ÓÚ¹¹½¨Ò»¸ö¡°¿ÉÒÆ¶¯µÄ¼ÒÍ¥Éú»î¿Õ¼ä¡± £¬ÎªÖйú¼ÒÍ¥Óû§Ìṩ¿Õ¼äÌåÑéÓëÖÇÄܳöÐнâ¾ö¼Æ»®¡£¸Ã³µ³µ³¤5200mm £¬¿í2025mm £¬¸ß1814mm £¬ÊÇ¡°º£ÄÚ×î¸÷ÈËÍ¥Öǻ۴óÎå×ùSUV¡± £¬¿í³¨×ù²ÕÉè¼Æ¿ÉÂú×ã¶ùͯ×ÔÓÉÔ˶¯¡¢×ð³¤ÊæÊÊÐÝí¬µÈ¶àÔª¼ÒÍ¥³öÐÐÐèÇó £¬ÕæÕýʵÏÖ¡°ÎÞÊø¸¿¡±µÄÈ«¼ÒÂóÌ¡£ÔÚÖÇÄÜ»¯·½Ãæ £¬á°Í¼Ì©É½X8½«´îÔØ»ªÎª×îÐÂÒ»´úÖÇÄÜ×ù²Õϵͳ £¬²¢Å䱸L3¼¶ÖÇÄܸ¨Öú¼ÝʻӲ¼þ £¬½øÒ»²½Ç¿»¯ÆäÔڸ߶ËÐÂÄÜÔ´SUVÊг¡µÄ½¹µã¾ºÕùÁ¦¡£¸Ã³µÐͽ«ÓÚ2026ÄêÉϰëÄêÕýʽÉÏÊÐ £¬ÊÇá°Í¼À©³äSUV²úÆ·¾ØÕóµÄÖØÒª³µÐÍ¡£

¡¶»´°²ÍÆÄÃСºúͬÊշѹ󲻹ó¡·

ÔÚĬɳ¶«µÄÖ×Áö²úÆ·ÏßÖÐ £¬ÅÁ²©ÀûÖéµ¥¿¹µÄרÀûÐüÑÂÈÕÒæÁÙ½ü £¬Ñ°ÕÒÏÂÒ»´úÔö³¤ÒýÇæÒÑÊÇÆä×î½¹µãµÄÕ½ÂÔÈÎÎñ¡£ÔÚÕâ¸öÀú³ÌÖÐ £¬×÷ΪÄܹ»ÓëÅÁ²©ÀûÖéµ¥¿¹ÁªÓõÄADC £¬Sacituzumab tirumotecan±»Ä¬É³¶«¼ÄÓèºñÍû¡£ÏÖ½×¶Î £¬sacituzumab tirumotecanËùÔÚµÄTROP2 ADCÁìÓò £¬ÊÇ×îÖËÊÖ¿ÉÈȵÄÑз¢ÈüµÀÖ®Ò»¡£ÆäÖÐ £¬ÏéÈðµÂµÄTrodelvy£¨¸êɳÍ×Öéµ¥¿¹£©¡¢°¢Ë¹Àû¿µºÍµÚÒ»Èý¹²ÏàÖú¿ª·¢µÄDatopotamab-deruxtecanµÈ £¬ÊÇ×îÍ·²¿µÄ¹ÜÏß £¬ÁìÏÈÓÅÊÆÃ÷ÏÔ¡£

¡¶ÒË´ºµÄÆß¼ÒÁë¿ì²Í°áÄÄÀïÈ¥ÁË¡·

½ØÖÁĿǰ £¬ËÄ´¨3101¸öÏçÕò(½ÖµÀ)ʵÏÖÒøÐÐÍøµãÈ«ÁýÕÖ £¬¼ÌÐø¼á³ÖÏçÕò°ü¹ÜЧÀͺÍÐÐÕþ´åÒøÐÐЧÀÍÈ«ÁýÕÖ¡£×ÅÁ¦Ö§³ÖÐÂʱ´ú¸ü¸ßˮƽ¡°Ì츮Á¸²Ö¡±½¨Éè £¬Á¸Ê³ÖصãÁìÓò´û¿îÓà¶îͬ±ÈÔö³¤47.94%¡£È«Ê¡128¸öÏØ(ÊÐ)ƽ¾ù´æ´û±Èͬ±ÈÌáÉý2.47¸ö°Ù·Öµã £¬66¸öÔ­¹ú¶¨Æ¶À§ÏØ¡¢25¸ö¹ú¼ÒÏç´åÕñÐËÖØµã°ï·öÏØ´û¿îÓà¶î»®·Öͬ±ÈÔö³¤13.19%¡¢16.7% £¬ÀۼƷ¢·ÅÍÑÆ¶ÈË¿ÚС¶îÐÅ´ûÁýÕÖÂʽÏÄê³õÌá¸ß11.79¸ö°Ù·Öµã¡£(Íê)

ÍøÕ¾µØÍ¼